CardiologyHealth Statusheart failure with preserved ejection fraction
Evaluating β-Blocker Use and Health Status in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT Trial
By MedXY|Oct 7, 2025
This analysis of the TOPCAT trial cohort evaluates the association between β-blocker use and health status in HFpEF patients, revealing no significant impact on baseline quality of life or modification of spironolactone benefits.
